Recent News

• 09.04.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Wells Fargo Healthcare Conference
• 08.27.2025 - Annexon Biosciences to Participate in Upcoming September Investor Conferences
• 08.18.2025 - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
• 08.14.2025 - Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
• 08.13.2025 - H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
• 08.07.2025 - Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
• 07.28.2025 - William “BJ” Jones
• 07.24.2025 - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Recent Filings

• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 8-K Current report
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.14.2025 - 144 Report of proposed sale of securities